Eli Lilly & Co.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5324571083
USD
1,014.49
-19.07 (-1.85%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.85 M

Shareholding (Mar 2025)

FII

13.43%

Held by 763 FIIs

DII

46.73%

Held by 117 DIIs

Promoter

10.18%

How big is Eli Lilly & Co.?

22-Jun-2025

As of Jun 18, Eli Lilly & Co. has a market capitalization of approximately $750.25 billion, with recent net sales of $49.00 billion and a net profit of $11.11 billion over the last four quarters.

Market Cap: As of Jun 18, Eli Lilly & Co. has a market capitalization of 750,252.66 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Eli Lilly & Co. reported net sales of 49,003.20 million and a net profit of 11,106.40 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 14,192.10 million, while total assets were reported at 78,714.90 million.

Read More

What does Eli Lilly & Co. do?

22-Jun-2025

Eli Lilly and Company is a large-cap pharmaceutical and biotechnology firm specializing in drug manufacturing. As of March 2025, it reported net sales of $12.73 billion and a net profit of $2.76 billion.

Overview:<BR>Eli Lilly and Company is engaged in the drug manufacturing business, specializing in pharmaceuticals and biotechnology, and operates within the large-cap market segment.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 12,728 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 2,759 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 750,252.66 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 47.00 <BR>Debt Equity: 2.24 <BR>Return on Equity: 97.65% <BR>Price to Book: 47.59 <BR><BR>Contact Details:<BR>Address: Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr INDIANAPOLIS IN : 46285-0001 <BR>Tel: 1 317 2762000 <BR>Website: https://www.lilly.com/

Read More

Who are in the management team of Eli Lilly & Co.?

22-Jun-2025

As of March 2022, the management team of Eli Lilly & Co. includes David Ricks as Chairman, President, and CEO, with Juan Luciano as Lead Independent Director and Independent Directors Raul Alvarez, Katherine Baicker, Carolyn Bertozzi, and Michael Eskew.

As of March 2022, the management team of Eli Lilly & Co. includes Mr. David Ricks, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Mr. Juan Luciano is the Lead Independent Director, while the Independent Directors are Mr. Raul Alvarez, Dr. Katherine Baicker, Dr. Carolyn Bertozzi, and Mr. Michael Eskew.

Read More

Is Eli Lilly & Co. overvalued or undervalued?

20-Sep-2025

As of September 12, 2025, Eli Lilly & Co. is considered overvalued with a high P/E ratio of 47 and other premium valuation metrics compared to peers, despite strong growth indicators and past outperformance of the S&P 500.

As of 12 September 2025, Eli Lilly & Co. has moved from fair to expensive in its valuation grade. The company is currently considered overvalued, as indicated by its high P/E ratio of 47, a Price to Book Value of 46.31, and an EV to EBITDA of 35.51. In comparison, peers such as Johnson & Johnson have a P/E of 26.18, and AbbVie, Inc. has a P/E of 25.28, highlighting Eli Lilly's premium valuation relative to its industry.<BR><BR>Despite a strong ROE of 97.65% and a PEG ratio of 0.87, which suggests growth potential, the valuation ratios indicate that the stock is priced significantly higher than its peers. Additionally, while Eli Lilly has outperformed the S&P 500 over the 3-year and 5-year periods with returns of 146.99% and 394.86% respectively, it has lagged in the 1-year and year-to-date comparisons, with returns of -15.70% and -1.17%. This performance underscores the concerns regarding its current valuation amidst a broader market context.

Read More

Is Eli Lilly & Co. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Eli Lilly & Co. shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite a mildly bearish monthly MACD and daily moving averages, while outperforming the S&P 500 in both short and long-term returns.

As of 31 October 2025, the technical trend for Eli Lilly & Co. has changed from mildly bearish to mildly bullish. The weekly MACD and Bollinger Bands are bullish, while the monthly MACD is mildly bearish. The daily moving averages indicate a mildly bearish stance. Dow Theory shows a mildly bullish trend in both weekly and monthly perspectives. <BR><BR>Eli Lilly has outperformed the S&P 500 across multiple periods, with a 1-week return of 9.73% compared to 0.71% for the S&P 500, and a 3-year return of 150.74% versus 76.66%. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 33.55%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 21.74

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 18.34%

 
4

With a growth in Net Profit of 105.14%, the company declared Very Positive results in Jun 25

5

With ROCE of 38.63%, it has a expensive valuation with a 14.99 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 699,433 Million (Large Cap)

stock-summary
P/E

47.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.99

stock-summary
Return on Equity

93.61%

stock-summary
Price to Book

38.28

Revenue and Profits:
Net Sales:
15,558 Million
(Quarterly Results - Jun 2025)
Net Profit:
5,660 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
36.56%
0%
36.56%
6 Months
32.47%
0%
32.47%
1 Year
22.25%
0%
22.25%
2 Years
73.22%
0%
73.22%
3 Years
170.7%
0%
170.7%
4 Years
313.1%
0%
313.1%
5 Years
583.39%
0%
583.39%

Eli Lilly & Co. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
18.34%
EBIT Growth (5y)
29.33%
EBIT to Interest (avg)
21.74
Debt to EBITDA (avg)
1.64
Net Debt to Equity (avg)
2.24
Sales to Capital Employed (avg)
0.94
Tax Ratio
18.34%
Dividend Payout Ratio
44.39%
Pledged Shares
0
Institutional Holding
89.11%
ROCE (avg)
33.55%
ROE (avg)
83.66%
Valuation key factors
Factor
Value
P/E Ratio
47
Industry P/E
Price to Book Value
46.31
EV to EBIT
38.80
EV to EBITDA
35.51
EV to Capital Employed
14.99
EV to Sales
15.62
PEG Ratio
0.87
Dividend Yield
0.00%
ROCE (Latest)
38.63%
ROE (Latest)
97.65%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 280 Schemes (29.65%)

Foreign Institutions

Held by 763 Foreign Institutions (13.43%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 22.23% vs -5.94% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 105.14% vs -37.43% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15,557.70",
          "val2": "12,728.50",
          "chgp": "22.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7,499.30",
          "val2": "5,764.60",
          "chgp": "30.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "249.00",
          "val2": "243.70",
          "chgp": "2.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "546.30",
          "val2": "-1,607.50",
          "chgp": "133.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5,660.50",
          "val2": "2,759.30",
          "chgp": "105.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "451.30%",
          "val2": "416.50%",
          "chgp": "3.48%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.00% vs 19.56% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 102.08% vs -16.08% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "45,042.70",
          "val2": "34,124.10",
          "chgp": "32.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18,806.60",
          "val2": "11,852.70",
          "chgp": "58.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "780.60",
          "val2": "485.90",
          "chgp": "60.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4,522.30",
          "val2": "-3,785.30",
          "chgp": "-19.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10,590.00",
          "val2": "5,240.40",
          "chgp": "102.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "378.30%",
          "val2": "302.60%",
          "chgp": "7.57%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
15,557.70
12,728.50
22.23%
Operating Profit (PBDIT) excl Other Income
7,499.30
5,764.60
30.09%
Interest
249.00
243.70
2.17%
Exceptional Items
546.30
-1,607.50
133.98%
Consolidate Net Profit
5,660.50
2,759.30
105.14%
Operating Profit Margin (Excl OI)
451.30%
416.50%
3.48%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 22.23% vs -5.94% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 105.14% vs -37.43% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
45,042.70
34,124.10
32.00%
Operating Profit (PBDIT) excl Other Income
18,806.60
11,852.70
58.67%
Interest
780.60
485.90
60.65%
Exceptional Items
-4,522.30
-3,785.30
-19.47%
Consolidate Net Profit
10,590.00
5,240.40
102.08%
Operating Profit Margin (Excl OI)
378.30%
302.60%
7.57%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 32.00% vs 19.56% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 102.08% vs -16.08% in Dec 2023

stock-summaryCompany CV
About Eli Lilly & Co. stock-summary
stock-summary
Eli Lilly & Co.
Pharmaceuticals & Biotechnology
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Company Coordinates stock-summary
Company Details
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr INDIANAPOLIS IN : 46285-0001
stock-summary
Tel: 1 317 2762000
stock-summary
Registrar Details